SulNOx Group PLC Grant of Options and Issue of Shares

RNS Number : 8010F

SulNOx Group PLC

26 September 2024

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION 11 OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019/310

 

26 September 2024

SulNOx Group Plc (the "Company" or "SulNOx")

 

Granting of Share Options

Issue of Shares

 

(Aquis Stock Exchange: SNOX)

 

Granting of Share Options

 

The board of directors of the Company (the "Board") announces that it yesterday granted share options to a director and certain employees and consultants. Part of these options grants are under an Enterprise Management Incentive scheme and part under an unapproved share option scheme.  A total of 980,000 options (the "Options") have been granted for ordinary shares of 2 pence each in the capital of the Company ("Ordinary Shares"), all with a 10-year life. 

 

530,000 of the Options have been granted with an exercise price of 40.0p, a small premium to the average closing price at which the Ordinary Shares traded for the last five days of 37.7 pence.  250,000 of these Options vest immediately, with the remainder subject to various vesting conditions.  250,000 of the Options have been granted with an exercise price of 36.0p, under an existing contractual arrangement, which includes certain vesting conditions. The remaining 200,000 Options have been granted with an exercise price of 45.0p, all with vesting conditions.

 

Issue of Shares to Consultants

 

The Company has issued a total of 44,788 new Ordinary Shares in settlement of invoices from consultants, made as follows: 

 

·    20,979 Ordinary Shares at a price of 35.75 pence per Ordinary Share in settlement of a liability of £7,500.00; and

·    23,809 Ordinary Shares at a price of 31.50 pence per Ordinary Share in settlement of a liability of £7,500.00.

 

The prices of the above issues have been calculated on the average share price for the period of time over which the services were delivered and the terms of the consultants' contracts.  An application will be made to admit the new Ordinary Shares for trading on AQSE Growth Market, which is anticipated to occur on or around 2 October 2024 ("Admission").

 

On Admission, the Company will have 121,550,946 Ordinary Shares in issue, each with one voting right. The Company does not hold any shares in treasury and therefore the total number of voting rights in the Company is 121,550,946. This figure should be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

 

- Ends -

 

For further information please contact:

 

SulNOx Group plc Steven Cowin, CFO	Tel: [phone]
Allenby Capital Limited (AQSE Corporate Adviser) Nick Harriss / John Depasquale	Tel: [phone]

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Alex Albertini
2	Reason for notification
a)	Position / status	NED
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	SulNOx Group plc
b)	LEI	21380011EU95E93AQN91
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 2 pence each   ISIN: GB00BJVQQP66
	Nature of the transaction	Grant of share options, subject to a market price of 50p at the time of exercise
c)	Price(s) and volumes(s)	Price(s) Volume(s) 40p   250,000
d)	Aggregated information Aggregated volume Price	N/A
e)	Date of the transaction	26 September 2024
f)	Place of the transaction	N/A

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NEXSEUSAMELSESU